Ecromeximab

Ecromeximab is a chimeric monoclonal antibody being developed for the treatment of malignant melanoma.[1][2]

Ecromeximab
Monoclonal antibody
TypeWhole antibody
SourceChimeric (mouse/human)
TargetGD3 ganglioside
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
Chemical and physical data
Molar mass145,255 g/mol
 NY (what is this?)  (verify)

The drug was developed by Kyowa Hakko Kogyo Co., Ltd. As of December 2015 development had been discontinued.[3]

References

  1. Statement On A Nonproprietary Name Adopted By The USAN Council - Ecromeximab, American Medical Association.
  2. Clinical trial number NCT00679289 for "Phase II Study of KW2871 Combined With High Dose Interferon-alpha2b in Patients With Metastatic Cutaneous Melanoma" at ClinicalTrials.gov
  3. Adis insight: Ecromeximab
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.